HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

2nd Edition of International Summit on Hematology and Blood Disorders

March 20-22, 2025

March 20 -22, 2025 | Madrid, Spain
Hematology 2023

Thoraya Mohamed Abdel Hamid

Thoraya Mohamed Abdel Hamid, Speaker at Hematology Conferences
Thoraya Mohamed Abdel Hamid
NCI Cairo University, Egypt
Title : The outcome of pediatric-inspired treatment protocols compared to adult protocol for management of Adolescent and Young Adults (AYAs) acute lymphoblastic leukemia patients

Abstract:

Aim: This retrospective study aimed to evaluate the efficacy and safety of adopting the pediatric-inspired ALL chemotherapy protocol in treating AYA patients diagnosed with ALL and to compare the clinical outcome with other adult ALL chemotherapy Protocol.

Methods: The study included all patients aged more than or equal to 18 and less than 40 years suffering from ALL/LBL who received treatment at Medical Oncology Department, National Cancer Institute, Cairo University in the period from January 2014 till December 2018.The study approved by the Institutional Review Board (IRB) NCI- Cairo University.

Results: Through this period, 169 patients were assessed and treated. The median age was 26 years (range 18-39 years) with male to female ratio of 1.86:1. Most of the patients (n=108) had received the modified Dana Faber Protocol.  Seven patients had received the Total XV protocol, while 54 cases had received modified GMALL protocol.  B-cell ALL was reported in 120 patients (72.7%) while 45 patients (27.3%) diagnosed with T-cell ALL. Molecular and cytogenetic analysis for patients with B-ALL showed t(9;22) in 26.7%, t (4;11) in 4.2% while t (12;21) in one case only(0.8%). Table 1 summarized the patients’ characteristics
 The pediatric-inspired regimens were well tolerated among our patients. When compared to the adult- protocol, the pediatric-inspired regimens were associated with significantly longer DFS (33 vs 18.8 months, p=0.046 Figure 1), While the OS was (26 vs 21 months, p=0.176 Figure 2), and CR rates (91% vs 86%, p=0.515). Also, the pediatric-inspired regimens were associated with lower incidence of septic shock during induction (24% vs 39%, p=0.013), lower incidence of early mortality (20% vs 33%, p=0.059), and shorter period of hospital stay during induction
 (Mean 31 vs 40 days, p<0.001).

Conclusion: AYA patients should be treated as a unique category of ALL patients. The pediatric-inspired chemotherapy regimens were well tolerated and it was associated with better outcomes in this group of patients.

Keywords: Leukemia, Lymphoblastic, Adolescents and Young Adult.

Biography:

Thoraya Mohamed Abdel Hamid is M.D in Medical Oncology NCI- Cairo University year 1999 and Professor of Medical Oncology/Haemato- Oncology at the NCI – Cairo University.

  • Different positions and training at the hemato/oncology group of Medical Oncology Department NCI-Cairo University since residency till current position.
  • Member of the American Society of Hematology International Members Committee (ASH- IMC) from January 2011 up till December 2018.
  • Special interest in lymphoid neoplasm with National and international clinical trials participations including CLL11 and Green study for CLL.
  • NCI – Cairo representative to the CLL Triallist Collaborative Group year 2007 to 2012.
  • Co-editor and reviewer at the Journal of the Egyptian National Cancer Institute.

Quick Links

Watsapp